Under the Paperwork Reduction Act of 1995, no persons are required to resp

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10076337		
iling Date		2002-02-15		
irst Named Inventor Wilme		ies, et al.		
Art Unit		3627		
Examiner Name Gera		ild J. O'Connor		
Attorney Docket Number		40655.3700		

					U.S.	PATENTS			Remove		_
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue E	Date	Name of Pate of cited Docu	entee or Applicant iment	Relev		Lines where ges or Relev	
	1	6067532		2000-0	5-23	Gebb					
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation p	lease click the	Add button.		Add		_
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	hber Kind Publication Name of Patentee or A of cited Document			Relev		Lines where ges or Relev			
	1										
If you wisl	h to a	dd additional U.S. Publ	shed Ap	plication	citatio	n information p	olease click the Ad	d buttor	-		
				FOREIG	SN PA	TENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country	y Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	+-
	1										С
If you wis	h to a	l dd additional Foreign P	atent Do	cument	citation	information pl	I lease click the Add	button	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		_
Examiner Cite Initiats* No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Τs					

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		. ++		2002-02-15		
		Filing Date				
		First Named Inventor Wilme		es, et al.		
		Art Unit		3627		
		ission under or or it ison	Examiner Name	Gera	ald J. O'Connor	
			Attorney Docket Number		40655.3700	
	_					
	١,	Copy of unpublished specificatio	n for 09/704,379 filed Novem	ber 2,	2002, entitled "System and Me	thod for Facilitating

10076227

Application Number

		EXAMINER SIGNATURE					
If you wish to add additional non-patent literature document citation information please click the Add button Add							
		Commercial Transactions Between Parties Residing at Remote Locations*					

Examiner Signature | Date Considered |
"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered, include copy of this form with next communication to applicant.

English language translation is attached.

See Kind Codes of USPTO Patent Documents at www.USPTO.GDV or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Jupanese patent documents, the notication of the year of the relign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Wind of document to the secretories enterior is an advantage of the document under Wind of document to the secretories enterior is patent and the secretories enteriories enteriories and the secretories enteriories and the secretories enteriories enteriories and the secretories a

	Application Number		10076337		
TION DIOO! COURT	Filing Date		2002-02-15		
TION DISCLOSURE	First Named Inventor	irst Named Inventor Wilmes, et al.			
ission under 37 CFR 1.99)	Art Unit		3627		
,	Examiner Name	Gera	ld J. O'Connor		
	Attorney Docket Number		40655.3700		

### CERTIFICATION STATEMENT

Please see 37	<b>CFR 1.97</b>	and 1.98	to make the	appropriate s	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

INFORMATION STATEME

That no item of information contained in the information disclosure statement was cited in a communication from a
foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
statement

See attached certification statement.

## Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

# None SIGNATURE

### A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the

ionii oi the signature.	Jill Of the signature.							
Signature	/Howard I Sobelman/	Date (YYYY-MM-DD)	2006-01-30					
Name/Print	Howard I Sobelman	Registration Number	39038					

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to late 4 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your require to complete this form and/or suggestions for reducing this burder, should be sent to the Chef information Ordinor, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 2213-1450, DO NOT SEND.

#### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is SU U.S. C. (2)(2)(2) (2) famishing of the information solicide is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademan Kolline is to process another examines your submission related to a patient application or patient. If you do not furnish the requested process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission, which may related the process and/or examines your submission, which may related the process and/or examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disease records.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S. C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, cuting an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make indemninations a partial individuals.
  - 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CPR 1-14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.